Introduction {#s1}
============

Estrogens fulfill a wide range of functions during development and differentiation in mammals of both sexes. In addition to these functions, they are also thought to play an important role in neuroprotection [@pone.0005153-Wang1]--[@pone.0005153-Wise1]. The actions of estrogens have been classified as either "genomic actions" or "non-genomic, rapid actions". The genomic actions are based on the capacity of the estrogen receptors (ERs) to bind to co-activators or co-repressors in order to enhance or inhibit the transcription of target genes, and it has been reported in many cell types (reviewed in [@pone.0005153-McKenna1]). This activity involves the dimerization of two receptor molecules mediated by the presence of the hormone and the generation of a macromolecular complex with co-regulators (reviewed in [@pone.0005153-Beato1]). The ERs belong to the nuclear receptor superfamily and two receptors, alpha and beta, have been identified (NR3A1 and NR3A2, according to the nomenclature of the NRN Committee [@pone.0005153-Kuiper1]. The structure of both receptors is similar containing a highly homologous DNA-binding region (95%) and a hormone binding region with weaker homology (69%), whereas the carboxy and amino-terminal regions are the most divergent regions (58% homology, reviewed in [@pone.0005153-Beato2]). Apart from this genomic action, estrogen can trigger rapid "non-genomic signaling" associated with the activation of second messengers. Among these, the activation of the mitogen activated protein kinase (MAPK) [@pone.0005153-Singh1], protein kinase C (PKC) [@pone.0005153-Cordey1] and phosphoinositide 3-kinase (PI3K) [@pone.0005153-Honda1] signaling pathways has been described. Indeed, cooperation with insulin-like growth factor-1 (IGF-1) has been demonstrated and ERα has been reported to associate with p85, the regulatory subunit of PI3K [@pone.0005153-Mendez1]--[@pone.0005153-CardonaGomez1]. Furthermore, estrogens may also act in a ligand-independent manner [@pone.0005153-Demay1] and they may exert certain antioxidant effects that are independent of their receptors.

We recently demonstrated that ERα is linked to PI3K associated "cytoplasmic signaling" in the brain and in primary neurons, where estradiol can induce the immediate activation of Akt/PKB and the subsequent inhibition of glycogen synthase kinase 3 (GSK3). On the light of the important role proposed for GSK3 in neuronal survival [@pone.0005153-Pap1] and in neuropathologies such as amyloid neurotoxicity [@pone.0005153-Xu1], the role of this new estradiol signaling pathway merits further analysis.

We also identified novel complexes in which ERα, GSK3 and β-catenin were associated, demonstrating that the action of estradiol transiently stabilized β-catenin, which is disassociated from the complex with ERα [@pone.0005153-CardonaGomez1]. The stabilization of β-catenin has been related with different functions of this protein. In addition to act in cell-cell adhesion, β-catenin also serves as a co-transcriptional regulator, modulating the functions of the T cell factor (TCF)/ lymphoid enhancer binding factor (LEF) proteins that are closely associated with Wnt signaling (reviewed in [@pone.0005153-Moon1]--[@pone.0005153-Barolo1]). Hence, the stabilization of β-catenin by estradiol may also have effects on gene transcription.

In this study we have assessed whether the β-catenin, stabilized by estradiol in neurons, may exert a significant effect at the transcriptional level. We show that the stabilization of β-catenin by estradiol is correlated with the inhibition of GSK3 in neuronal-like cells (N2a-m), as well as in cortical neurons. Indeed, estradiol increased TCF/LEF-1 transcription in a dose-dependent manner. This increase in transcription was partially prevented by the addition of an estradiol antagonist and was mimicked by an alpha and beta specific-agonist. In neuronal cells, estradiol induced the formation of a TCF-DNA complex that was impaired by the presence of antibodies against LEF-1. Moreover, in cortical neurons from a TCF/LEF-1--βgal transgenic mouse, β-galactosidase activity was up-regulated by the action of estradiol. Finally, in a LEF-1 mutant cell line, we identified some genes that were differentially regulated by estradiol.

Together, all these data demonstrate that in addition to its nuclear action mediated through the ER, estradiol triggers a signal that recruits β-catenin and LEF-1 and that may be responsible for more wide-ranging actions of this hormone, at least in neurons.

Results {#s2}
=======

Estradiol transiently regulates the phosphorylation of GSK3 and the amount of β-catenin in N2a-m neuronal cells and cortical neurons {#s2a}
------------------------------------------------------------------------------------------------------------------------------------

We recently demonstrated that estradiol inhibit GSK3 and stabilize β-catenin in the hippocampus and in hippocampal neurons. To further analyze this phenomenon, it was necessary to transfect neuronal cells. We first examined whether neuroblastoma cells behave like primary neurons concerning this estrogenic action. We found that **N2a-m** cells, a clone derived from NB2a (ATCC: CCL 131) and that has been maintained for several years in our laboratory, responded to estradiol in a similar manner as primary neurons, as demonstrated below.

The effect of estradiol on this cell line was examined and we initially determined whether N2a-m cells expressed both α and β estrogen receptors when maintained in serum--free medium (Supplementary [Figure S1](#pone.0005153.s001){ref-type="supplementary-material"}). When N2a-m cells were exposed to estradiol, ERα-immunoreactivity became more concentrated in the nucleus in a time and dose dependent manner (Supplementary [Figure S1](#pone.0005153.s001){ref-type="supplementary-material"}). Thus, since these cells respond to estradiol and can be efficiently transfected, we analyzed whether exposure to estradiol could modify GSK3β-PSer using primary cortical neurons as a reference in parallel. Immunoreactivity against GSK3β-PSer was increased in N2a-m cells exposed to estradiol, reaching a maximum (5±1 fold, n = 4) 60--90 minutes after the addition of the hormone ([Figure 1A](#pone-0005153-g001){ref-type="fig"}). A similar time-course of GSK3β-PSer immunoreactivity was observed in cortical primary neurons ([Figure 1C](#pone-0005153-g001){ref-type="fig"}), reaching a maximum increase (2.2±0.5 fold; n = 3) 90 minutes after exposure to the hormone. The increase in serine phosphorylation of GSK3β was dose-dependent and was maximal in the range of 100 to 200 nM (2.5±0.5 fold; n = 3, [Figure 1A](#pone-0005153-g001){ref-type="fig"}).

![Treatment of estradiol increases Ser^9,21^-GSK3 phosphorylation and β-catenin accumulation in neuronal cells.\
(A)-Neuroblastoma N2a-m were treated with different doses of estradiol and for different times (20--120 min with 10--500 nM) and the maximum increase in GSK3β-PSer^9^ was observed when they were treated for 60 min with 100--200 nM estradiol. (B)- Stabilization of β-catenin. N2a-m cells treated with estradiol showed a clear increase in β-catenin that could be prevented by prior exposure to ICI 182780 (used 100× concentrated in comparison to estradiol), 60 minutes before estradiol treatment (lower panel). (C)-Cortical Primary Neurons (2DIV) were treated with estradiol (100 nM) and the maximum increase in GSK3β-PSer^9^ and the subsequent stabilization of β-catenin was clearly detected 60--90 min after the onset of exposure. In all cases diagram shows the mean normalized densitometry values and the corresponding standard deviations from at least three independent experiments. Asterisks indicate statistical significance (Student\'s t-test) \*\* (P≤0.05), \* (P≤0.01). The single \* or \*\* compares data to control whereas the bar between different points shows statistical differences between experimental values.](pone.0005153.g001){#pone-0005153-g001}

The second important element in our analysis is β-catenin, as demonstrated in hippocampal neurons [@pone.0005153-CardonaGomez1]. Thus, we determined whether inhibition of GSK3 was correlated with the stabilization of β-catenin in cell extracts from N2a-m and cortical neurons treated with estradiol (100 nM). The total amount of β-catenin increased in both N2a-m cells (3.5±0.5 fold; n = 3) ([Figure 1A](#pone-0005153-g001){ref-type="fig"}) and cortical neurons (2.2±0.3 folds, n = 3) ([Figure 1C](#pone-0005153-g001){ref-type="fig"}), with a time-course similar to that of the changes in GSK3-PSer ([Figure 1 A and B](#pone-0005153-g001){ref-type="fig"}). The increase in the stabilization of β-catenin by estradiol was prevented by ICI 182780, a specific ER receptor antagonist (*ICI/estradiol ratio was maintained 100×*) ([Figure 1B](#pone-0005153-g001){ref-type="fig"}).

A complex of ER α and β-catenin was recently detected in the hippocampus of female ovariectomized rats [@pone.0005153-CardonaGomez1]. We assessed whether a similar complex was present in extracts from N2a-m cells. Our data showed that β-catenin was detected in complexes immunoprecipitated with antibodies against ERα or ERβ ([Figure 2](#pone-0005153-g002){ref-type="fig"}). Similarly, both GSK3α and β were detected in these complexes, although there was less GSK3 recovered when antibodies against ERα were used. As a positive control in these experiments, material was immunopreciptated with an antibody against Adenomatous Polyposis Coli protein (APC) and in these latter experiments, mostly GSK3β was detected ([Figure 2](#pone-0005153-g002){ref-type="fig"}).

![Estrogen receptors form a complex with β-catenin and GSK3 in N2a-m cells.\
ERα and ERβ were immunoprecipitated from N2a-m cells, and similar endogenous protein complexes were observed with both antibodies. Immunoprecipitation with an anti-APC antibody is shown as an internal control of a β-catenin interacting protein. Both GSK3 isoforms were detected in the immunocomplex recovered with ERα or ERβ antibodies, whereas GSK3β is the major isoform recovered with APC antibodies, used as a positive control. The immunoprecipitation also shows a fraction of β-catenin associated with both ER isoforms. IgG\'s represent the IP using irrelevant IgGs as a negative control.](pone.0005153.g002){#pone-0005153-g002}

Estradiol increase the association of β-catenin to the neuronal membrane fraction {#s2b}
---------------------------------------------------------------------------------

Given that β-catenin may fulfill two distinct cellular functions, as an adhesion molecule or as co-transcription factor. Two different pools have been described associated with different functions [@pone.0005153-Moon1], [@pone.0005153-Bienz1]. Thus, we determined whether estradiol-mediated stabilization augmented either of the putative β-catenin pools. Membrane and nuclear fractions were obtained from cultured neurons exposed to the hormone for 30 and 60 minutes. Interestingly, the amount of β-catenin detected in the membrane fraction was increased at 30 and 60 minutes after exposure to estradiol whereas the nuclear fraction was almost unaffected (Supplementary [Figure S2](#pone.0005153.s002){ref-type="supplementary-material"}).

Estradiol activates TCF-mediated transcription {#s2c}
----------------------------------------------

Even though accumulation of β-catenin in the cell nucleus could not be perceived at the biochemical level, we assessed whether estradiol might induce β-catenin mediated transcriptional activation. For this purpose we transfected N2a-m cells with a TCF-luciferase reporter (TOPFlash) in combination with an EGFP reporter. When estradiol (100 nM) was added after cell transfection, luciferase activity increased 24±4 fold (n = 4, [Figure 3D](#pone-0005153-g003){ref-type="fig"}), reaching a maximum 60--90 minutes after hormonal exposure ([Figure 3A](#pone-0005153-g003){ref-type="fig"}). The estradiol-induced increase in luciferase activity was time and concentration-dependent ([Figure 3A--B](#pone-0005153-g003){ref-type="fig"}). Moreover, the transcriptional activity depended on ERs since it was drastically reduced when the ER antagonist ICI 182780 was applied in conjunction with estradiol ([Figure 3C](#pone-0005153-g003){ref-type="fig"}). In parallel, when we transfected N2a-m cells with a mutated form of the TCF reporter (FOPFlash) we were unable to detect *luciferase* activity ([Figure 3C](#pone-0005153-g003){ref-type="fig"}).

![Estradiol augments TCF/LEF-dependent transcription in N2a-m cells.\
N2a-m cells were transfected with the TOPFlash or FOPFlash reporter plasmid with EGFP-pCDNA3, and the cells were then treated with estradiol and other test compounds for the different times and at the different concentrations indicated. (A--B), Soluble extracts from estradiol treated cells were obtained and *luciferase* activity was measure as indicated in the [Methods](#s4){ref-type="sec"}. The normalized data were expressed in relative light units (RLU) compared to the control solvent, and the response was maximal at 60 min using 100 nM. (C).The effect of estradiol can be prevented by prior exposure to the ER antagonist ICI 182780 10 µM for 2 hr. (D), Specific agonists of each estrogen receptor (PPT: ERα agonist, and DPN: ERβ agonist, at two concentrations, 5 and 10 nM) also induced TCF/LEF-mediated transcription although PPT was more efficient than DPN. The graphs show the normalized *luciferase* activity from at least three independent experiments. The P value from the Student\'s t-test was \* (P≤0.05), \*\* (P≤0.01). The single \* or \*\* compares data to control whereas the bar between different points shows statistical differences between them.](pone.0005153.g003){#pone-0005153-g003}

To determine whether this transcriptional activation was associated with ER α or ER β, we used two specific agonists of either the α or β receptor isoforms. Both 4,4′,4″-(propyl-\[(1)H\]-pyrazole-1,3,5-triyl) trisphenol (PPT, α-selective) and 2,3-bis (4-hydroxyphenyl) propionitrile (DPN (β-selective) agonists increased transcriptional activity in N2a-m cells, although the activity mediated by PPT was more prominent that that mediated by DPN, suggesting that ER α is more effectively coupled to this novel pathway ([Figure 3D](#pone-0005153-g003){ref-type="fig"}). As a positive control of this TCF-reporter, we took advantage of the fact that this neuronal cell responds to some Wnt proteins and thus, β-catenin stabilization was detected when N2a-m cells were exposed to Wnt3a (Supplementary [Figure S3](#pone.0005153.s003){ref-type="supplementary-material"}). When we exposed cells to Wnt3a after TOPFlash transfection, the transcriptional activation obtained in response to Wnt3a was similar to that obtained after estradiol treatment (Supplementary [Figure S3](#pone.0005153.s003){ref-type="supplementary-material"}).

The expression of a TCF-β-galactosidase reporter, as well as an engrailed-1 promoter luciferase reporter, is modulated by estradiol in primary neurons {#s2d}
------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether estradiol can regulate the expression of a reporter controlled by TCF in primary neurons, we used two complementary approaches. First, we transfected TOPFlash or FOPFlash into primary neurons ([Figure 4A](#pone-0005153-g004){ref-type="fig"}) and after TOPFlash transfection, we detected an increase in luciferase activity (4.8±1.2 folds; n = 3) in the presence of estradiol (100 nM), which was not induced after FOPFlash transfection ([Figure 4A](#pone-0005153-g004){ref-type="fig"}). High concentrations of insulin (ITS supplements) also produced a 10-fold increase in these cells as a positive control ([Figure 4A](#pone-0005153-g004){ref-type="fig"}). In a second approach, we obtained primary cultures of cortical neurons from TCF-βgal transgenic mice, a colony designed to analyze the activation of the Wnt pathway in vivo [@pone.0005153-DasGupta1]. We detected β-galactosidase expression in almost all cortical neurons of TCF-βgal transgenic mice ([Figure 4B](#pone-0005153-g004){ref-type="fig"}) and thus, we analyzed the amount of β-galactosidase after exposure to either estradiol or Wnt3a. Both estradiol and Wnt3a produced a similar moderate increase in β-galactosidase, assessed in western blots ([Figure 4B](#pone-0005153-g004){ref-type="fig"}). This finding was confirmed by quantitative RT-PCR in parallel experiments. Hence, in total RNA obtained from cultured cortical neurons, a similar increase in the expression of the LacZ-transgene was detected by RealTime RT-PCR after exposure to Wnt3a or estradiol when normalized to actin mRNA expression ([Figure 4C](#pone-0005153-g004){ref-type="fig"}).

![Estradiol increase TCF/LEF-dependent transcription in cortical neurons.\
(A)-Cortical neurons from E18 embryos were nucleofected with TOPFlash or FOPFlash reporter plasmids and luciferase activity was analyzed after 2DIV. Estradiol treatment (60 min, 100 nM) selectively increased transcription from the TOPFlash reporter plasmid compared to FOPFlash, which shows no activity. Insulin treatment (5 µg/ml) was used as a control of induction. (B--C)- Expression of the LacZ gene in response to estradiol in transgenic mice. The scheme represents the lacZ transgene under the control of three consensus TCF/LEF-binding motifs upstream of the c-fos promoter, as described in [*Materials and Methods*](#s4){ref-type="sec"}. (B)-Upper panel. Total extracts of cortical neurons (2DIV) were obtained from a TCF/LEF-lacZ transgenic mouse (see [Materials and Methods](#s4){ref-type="sec"}) and the β-galactosidase (β-gal) expression was assessed in western blots after estradiol treatment (100--200 nM) for 3 h. Wnt3a (20 ng/ml) was used as a control of TCF-mediated induction. A slight increase in β-gal protein was observed after exposure to estradiol, as with recombinant Wnt3a protein. (B), Lower panel. Basal expression of β-galactosidase in neurons from transgenic mice was assessed by immunocytochemistry using specific antibodies against β galactosidase (green) and Phalloidin-labelled with Alexas 549. (C), Alternatively, after treatment with estradiol or Wnt3a, total Lac Z expression was quantified by RT-PCR using specific β-gal oligonucleotides and using actin (a housekeeping gene) as an internal standard (see [*Methods*](#s4){ref-type="sec"}). The amplification of both genes was analyzed on agarose gels and the graph represents the normalized data obtained from the Lightcycler analysis. Both treatments clearly increase transcriptional activity when compared to controls.](pone.0005153.g004){#pone-0005153-g004}

As a complementary alternative we try to analyze whether an endogenous promoter may be regulated by estradiol in a similar fashion as Wnt3a. For that purpose we used a construct containing a 2.8 Kb region of the Engrailed-1 promoter that has three LEF-1 sites situated upstream of a luciferase gene pENP1*Luc* [@pone.0005153-McGrew1] (see scheme in [Figure 5A](#pone-0005153-g005){ref-type="fig"}). Again luciferase expression was clearly driven by estradiol, although at identical amounts of cDNA the response of TOPFlash was more potent ([Figure 5B](#pone-0005153-g005){ref-type="fig"}).

![The engrailed 1-*luciferase* construct responds to estradiol.\
The scheme represents the structure of the 2.8 kB of construct containing the proximal region of endogenous *engrailed* 1 promoter bind to luciferase reporter. N2a-m cells were transfected with the pENP1-luciferase reporter plasmid (*250*, *200 and 750 ng*) (represented as 0.25, 0.5, 0.75), which contains three LEF-1 sites (see upper panel). The Lower panel shows a comparison of the induction of TOPFlash (*750 ng*) and pENP-luc in this cell line. Although basal levels of luciferase activity are lower in the pENP1-luc reporter plasmid, estradiol induces this activity to 3-fold that of the control levels, as shown in the right panel. The graph in B shows the normalized *luciferase* activity from at least three independent experiments. The P value from the Student\'s t-test was \*\* (P≤0.01) when compared with control data.](pone.0005153.g005){#pone-0005153-g005}

Does estradiol use a β-catenin/TCF transcription system similar to that used by Wnt? {#s2e}
------------------------------------------------------------------------------------

The mechanism by which Wnt modulates β-catenin-mediated transcription is sensitive to the phosphorylation of β-catenin as well as to β-catenin/TCF binding (reviewed in [@pone.0005153-Mulholland1]). Thus, when we transfected N2a-m cells with different amounts of a constitutively active mutant of β-catenin (S33Y), the transcriptional activity in extracts of these cells was almost maximal and it was virtually insensitive to the addition of estradiol (15--20%), when compared with 5--12 folds induction (control or mock-transfected cells *versus* estradiol) ([Figure 6A](#pone-0005153-g006){ref-type="fig"} *versus* [Figure 3B--C](#pone-0005153-g003){ref-type="fig"}). In all these experiments, the total amount of β-catenin after transfection and treatment was controlled to ensure that it did not influence the results ([Figure 6B](#pone-0005153-g006){ref-type="fig"}). Hence, these data strongly suggested that estradiol-mediated transcription requires the formation of a β-catenin/TCF complex. Indeed, when a version of LEF-1 that is truncated in the β-catenin binding region (Δ56LEF-1) [@pone.0005153-Hsu1] was transiently transfected into N2a-m neuroblastoma cells in combination with TOPFlash, estradiol did not drive *luciferase* expression ([Figure 6C](#pone-0005153-g006){ref-type="fig"}), whereas N2a-m-*mock* transfected cells responded to estradiol as previously shown.

![Interaction of β-catenin/LEF-1 mediates the transcriptional capacity of estradiol.\
(A)-β-catenin/TCF estradiol-mediated transcription depends on the phosphorylation of β-catenin. N2a-m cells were transfected with different amounts of the S33Y-βcatenin (S33Y-βcat) expression plasmid as indicated (*250 or 500 ng*). (B)-β-catenin levels in total extracts from cells transfected with S33Y-βcat or the empty cDNA3.1 plasmid, representative of the analysis of lanes (0.5+); and (0.5−) in A. Under the high levels of S33Y-βcat expression estradiol was virtually unable to further induce reporter expression. No statistical differences are founded between the bars data from different experiments. (C)-Interaction of β-catenin with TCFs is essential for estradiol to induce gene transcription through TCF sites. Endogenous LEF-1 protein levels remain unchanged after estradiol treatment for 60--90 min, as seen with the anti-N terminal LEF-1 antibody. Expression of the Δ56LEF-1 protein was detected in western blots after transfection of increasing amounts of plasmid (*400 or 600 ng*) using an antibody against the HMG box region of LEF-1. The overexpression of a LEF-1 mutant construct (Δ56LEF-1) prevents estradiol from inducing expression from the TOPFlash reporter plasmid when compared with *mock*-transfected cells. (D)-Δ56LEF-1 reduces estradiol induced luciferase expression from pENP1*-luc*. The overexpression of Δ56LEF-1 construct reduced the luciferase activity induced by estradiol from the pENP1-Luc plasmid, when compared with *mock*-transfected cells (*empty*-pcDNA3). Estradiol (E) induced luciferase activity to 8--15 fold that of the control levels (C and E), in the pENP1-luc reporter. However, the expression of Δ56LEF-1 diminished this induction (compare pCDNA3+E *versus* Δ56+E). In both cases (C--D), the graphs show the normalized *luciferase* activity (RLU) from at least three independent experiments. The P value from the Student\'s t-test was \* (P≤0.05).](pone.0005153.g006){#pone-0005153-g006}

Similarly, when we transiently transfected into N2a-m neuroblastoma cells with Δ56LEF-1 in combination with pENP1 *Luc*, the *luciferase* expression estradiol-mediated was severely reduced by the expression of LEF1-mutant ([Figure 6D](#pone-0005153-g006){ref-type="fig"}).

Are β-catenin/TCF-DNA complexes activated by estradiol? {#s2f}
-------------------------------------------------------

To determine whether the estradiol-mediated transcriptional activation detected in our study relies on similar complexes to those described for Wnt, we assayed the DNA-protein complexes with TCF-binding sequence in nuclear extracts from N2a-m cells (*EMSA assay*). We detected a DNA-protein complex that was more evident after estradiol or Wnt3a treatment ([Figure 7](#pone-0005153-g007){ref-type="fig"}). Moreover, the formation of this complex was impaired by pre-incubation with the ER antagonist ICI 182780 and the detection of the complex could be competed with unlabelled TCF-oligonucleotide but not by a mutant TCF oligonucleotide ([Figure 7 A](#pone-0005153-g007){ref-type="fig"}).

![The LEF-1-DNA complex is detected in nuclear protein extracts and it is modulated by estradiol.\
(A)-Identification of the specific band by competition with non-labeled wt oligonucleotides. Nuclear proteins were obtained from N2a-m cells treated for 30 minutes with estradiol, ICI or Wnt3a, enabling specific TCF-DNA complexes to be detected. In control nuclear extracts the presence of a pre-established TCF-DNA complex was detected, which augmented slightly in the presence of estradiol and that decreased upon ICI treatment. The arrow indicates the complex. (B)-Analysis of the identity of the TCF-DNA complex. Antibodies against TCF1, LEF-1, or irrelevant IgGs (C) were added to the nuclear protein extracts and modification of the DNA/protein complex was evaluated. In addition, antibodies against TCF3 or ERα were used in parallel experiments, without producing any modification of this pattern (Supplementary [Figure S4](#pone.0005153.s004){ref-type="supplementary-material"}). Only in the case of the anti-LEF-1 antibody was a more slowly migrating band observed. The arrow with an asterisk indicates the appearance of a higher molecular weight complex.](pone.0005153.g007){#pone-0005153-g007}

Four members of TCF family have been described (TCF1, LEF-1, TCF3, and TCF4), the first three of which are found in neuronal tissues [@pone.0005153-Galceran1]. To determine which of these may participate in the TCF/DNA complex described in our system, we pre-incubated the nuclear extracts with specific antibodies against TCF1, LEF-1 or TCF3, as well as with antibodies against ERα or irrelevant IgGs. The antibody against LEF-1 abolished the formation of the DNA-protein complex while the antibodies against TCF1, TCF3 and ERα did not appreciably modify the DNA-protein complex ([Figure 7B](#pone-0005153-g007){ref-type="fig"} and supplementary [Figure S4](#pone.0005153.s004){ref-type="supplementary-material"}).

Are the genes regulated by estradiol/β-Catenin/LEF-1 similar to those regulated by Wnt/β-Catenin/TCFs? {#s2g}
------------------------------------------------------------------------------------------------------

Together, the data obtained so far suggested that estradiol might activate a β-Catenin/LEF-1 complex that is similar to that activated by Wnt in other systems. Thus, to shed further light on this new molecular mechanisms, we took advantage of the fact that the Δ56LEF-1 construct may act as a dominant-negative construct and we generated N2a-m cells stably transfected with Δ56LEF-1 ([Figure 8A](#pone-0005153-g008){ref-type="fig"}). This cell line presented a more differentiated morphology, with bipolar extension of two processes ([Figure 8A](#pone-0005153-g008){ref-type="fig"}).

![Generation of a stable N2a-m cell line expressing the Δ56LEF-1 protein.\
N2a-m cells were co-transfected with Δ56LEF-1 or the empty pCDNA3 vector containing the Puromycin resistance gene (for details see [*Methods*](#s4){ref-type="sec"}). (A)- N2a-m-Δ56LEF-1 expression was observed by dual immunocytochemistry using an LEF-HMGbox antibody (green) and Phalloidin (red). Note the morphological changes associated with the expression of LEF-1 mutant. (B)- RNA from the different stable N2a-m cell lines was obtained and the RT-PCR products were analyzed in agarose gels. Expression of the Δ56LEF-1 plasmid was tested using oligos specific to the Δ56LEF-1 plasmid, in parallel with specific oligos recognizing endogenous LEF-1 protein (LEF-1-wt) as controls. Note that no significant differences in plasmid expression were observed between cells growing in 10% FCS compared to those grown in the absence of FCS. (C)-Protein expression was determined to test for the presence of the mutant LEF-1 protein in N2a-m cells. Nuclear extracts were prepared from control and estradiol treated cells, and little accumulation of β-catenin was detected after exposure to estradiol although the estrogen receptor does enter the nucleus. The LEF-HMG box antibody allows us to differentiate full-length LEF-1 from Δ56 LEF-1 in western blots. Nucleolin levels were used as an internal control. The right insert represents the luciferase activity (RLU) of both stable cell lines. A functional analysis was performed to check the loss of estradiol induction over TOPFlash in these cells, as previously reported for the transient transfection ([Figure 6C](#pone-0005153-g006){ref-type="fig"}). The graph shows the normalized *luciferase* activity from at least three independent experiments. The P value from the Student\'s t-test was \*\* (P≤0.01) when compared with control data.](pone.0005153.g008){#pone-0005153-g008}

As an internal control, we analyzed the presence of the Δ56LEF-1 as well as the endogenous LEF-1. The expression of Δ56LEF-1 in this cell line was not drastically impaired, and it was maintained at an mRNA and protein ratio of at least 1∶1 when compared with LEF-1, in a cell line *mock*-transfected with the empty pcDNA3.1 vector ([Figure 8B and C](#pone-0005153-g008){ref-type="fig"}). The dominant-negative activity of the LEF-1 mutant was observed when the cell line was transiently transfected with TOPFlash. The expression of *luciferase* was still blocked when the cells were incubated with estradiol, as described previously ([Figure 8C](#pone-0005153-g008){ref-type="fig"}). Even though, estrogen receptor and β-catenin may be detected in the nuclear fraction of these transfected cells ([Figure 8C](#pone-0005153-g008){ref-type="fig"}).

Subsequently, stably transfected N2a-m cells were utilized to obtain the total RNA, either from *empty* pcDNA3/N2a-m (group **A**) or Δ56LEF-1/N2a-m (group **B**). In both cases, cells were treated with estradiol or Wnt3a for 60 minutes and then total RNA was purified. Gene expression from the two stable cell types (*A and B*) was then analyzed using the Applied Biosystems Mouse Genome Survey Microarray (*Applied Biosystems*).

Genes were normalized with respect to control untreated cells, and divided in different groups. From these groups, we only consider those with differences when compared group **A** versus group **B**, for each treatment. From these we selected those with a log~2~R higher or lower than **1**, being 102 genes upregulated and 121 genes downregulated by estradiol; and 137 genes upregulated and 166 genes downregulated by Wnt3a. [**Table 1**](#pone-0005153-t001){ref-type="table"} described the list of the annotated genes present in the protein bank with the *Ref Seq* and the *Gene Name*. In contrast, the genes modified only after estradiol treatment or only after Wnt3a treatment that presented no significant differences between **A** and **B** were discarded. Initially, for the confirmation of the putative deferential response of both cells (A vs B) we selected two genes presented in both arrays that were modified by Wnt as well as by estradiol (Plasminogen and LEF-1). A final validation was performed using specific antibodies against the selected proteins ([Figure 9](#pone-0005153-g009){ref-type="fig"} and [8C](#pone-0005153-g008){ref-type="fig"}). Thus, plasminogen expression in Δ56LEF-1 cells was 2.5 fold higher, although these initial differences were not considerably augmented by treatment with Wnt or estradiol. Similarly, the endogenous LEF-1 was reduced by the presence of the mutant version of this protein ([Figure 8](#pone-0005153-g008){ref-type="fig"}). In addition we selected some genes, previously reported by other laboratories as Wnt targets , such as TCF\'s, Cyclin D, Myc, MMP\'s (for updated, please check, The Wnt Homepage, *at* <http://www.stanford.edu/~rnusse/pathways/targets.html>).

![Gene expression of cDNA/N2a-m and Δ56LEF-1/N2a-m cells after exposure to estradiol.\
(A)- Gene expression profile in cDNA/N2a-m and Δ56LEF-1/N2a-m stables cell lines. The upper panel reflects the gene induction of some selected genes, in microarray analysis of RNA collected after a 45 min exposure to estradiol or Wnt3a to detect the early response. Data is expressed as log~2~R from cDNA/N2a-m cells, that we denoted as group A, and Δ56LEF-1/N2a-m cells, that we denoted as group B. The effect of the treatment was compared between the two stable cell lines (A vs B) (see "[Table 1](#pone-0005153-t001){ref-type="table"}" for a more complete list of the annotated genes). As seen, in the panel we selected some "putative Wnt-regulated genes", such as *Tcf3*, *Ccnd1* (cyclin D1), *GSK3b*, *Myc* and *LEF-1*, to give some examples of the results in our arrays. We detected changes at the protein level only in *Plg*, although there were several genes whose expression varied. For example, the levels of plasminogen RNA were much higher in group B than group A (ratio AvsB≥1), and the expression of LEF-1 was higher in Δ56LEF-1 due to the mutant expression (ratio AvsB≤−1). The western blots below are verifications of these differences at the protein level. Among other proteins that did not change between the groups of cells were GSK3 β or myc (see western blots on the right). MMP-2 was tested although it did not display a change in its RNA levels and there was no difference in the total cell extracts. Interestingly, when conditioned medium was prepared, more pro-active MMP-2 (and less active protein) was seen in Δ56LEF-1 cells. \[Gene_Symbol: *Plg* (plasminogen), *Tcf3*, *Ccnd1* (cyclin D1), *GSK3b*, *Myc* and *LEF1*\]. (B)- Estradiol induction of N-cadherin and cyclin D2 may be affected by expression of the Δ56LEF-1 protein. Total cell extracts from cDNA/N2a-m cells (group A) and Δ56LEF-1/N2a-m cells (group B) were collected 24 h after estradiol or Wnt3a treatment to analyze several known Wnt or estrogen target genes. As seen in western blots, estradiol upregulated E-cadherin, N-cadherin and cyclin D2 expression in group A cells. N-cadherin and cyclin D2 were also upregulated by Wnt in group A cells. In contrast, E-cadherin expression was not Wnt responsive. The regulatory effects of estradiol on E-cadherin, N-cadherin and cyclin D2 expression were lost when Δ56LEF-1 is expressed, as seen in group B cells. In the case of E-cadherin, the loss of functional LEF-1, which acts as a known gene repressor, implies higher protein levels even without stimulation. In contrast, levels of actin or cyclin D1 remained unchanged.](pone.0005153.g009){#pone-0005153-g009}
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###### Results of the Microarray analysis of gene transcription.

![](pone.0005153.t001){#pone-0005153-t001-1}

  UPREGULATED:           
  -------------- ------- -------------------------------------------------------------------------------------------
  NM_007990.1     2,739   Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived)
  NM_133198.1     2,676                                 liver glycogen phosphorylase
  NM_130888.1     2,457                                  nuclear RNA export factor 7
  NM_025703.2     2,439                                  RIKEN cDNA 3930402F23 gene
  NM_183271.1     2,181                                  RIKEN cDNA 1700049M11 gene
  NM_008877.2     2,039                                        **plasminogen**
  NM_007407.2     2,034                     adenylate cyclase activating polypeptide 1 receptor 1
  D87975.1        1,994                 serine (or cysteine) proteinase inhibitor, clade F, member 1
  NM_019703.2     1,890                                 phosphofructokinase, platelet
  NM_010480.4     1,847                                  heat shock protein 1, alpha
  NM_054095.1     1,846                               EF hand calcium binding protein 2
  NM_013779.1     1,701                                 melanoma antigen, family L, 2
  NM_021389.3     1,653                              SH3-domain kinase binding protein 1
  NM_009529.1     1,509                                Xlr-related, meiosis regulated
  NM_133362.1     1,491                             erythroid differentiation regulator 1
  NM_183294.1     1,487                     cyclin-dependent kinase-like 1 (CDC2-related kinase)
  NM_007833.1     1,462                                            decorin
  BC053970.1      1,337                  NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
  NM_008144.3     1,335                 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)
  NM_033325.1     1,332                                     lysyl oxidase-like 2
  NM_175027.2     1,321                                    cDNA sequence BC022692
  NM_146034.1     1,316                   meningioma expressed antigen 6 (coiled-coil proline-rich)
  NM_177752.2     1,313                                hypothetical protein 6820428D13
  NM_025437.2     1,298                     eukaryotic translation initiation factor 1A, Y-linked
  NM_019768.2     1,291                                   mortality factor 4 like 2
  NM_008590.1     1,251                                 mesoderm specific transcript
  NM_019647.3     1,247                                     ribosomal protein L21
  NM_031174.2     1,246                             Down syndrome cell adhesion molecule
  NM_009093.1     1,237                                     ribosomal protein S29
  NM_008200.1     1,225                            histocompatibility 2, D region locus 4
  NM_008033.2     1,222                             farnesyltransferase, CAAX box, alpha
  NM_026712.1     1,216                                  RIKEN cDNA 0610030H11 gene
  NM_183203.1     1,202                                hypothetical protein 9130430E04
  NM_145628.2     1,200                                ubiquitin specific protease 11
  NM_207204.1     1,188                                  RIKEN cDNA 4930519N13 gene
  NM_025695.2     1,178                  SMC6 structural maintenance of chromosomes 6-like 1 (yeast)
  NM_008183.2     1,177                                glutathione S-transferase, mu 2
  NM_145526.1     1,173                     purinergic receptor P2X, ligand-gated ion channel, 3
  NM_012035.1     1,136              transient receptor potential cation channel, subfamily C, member 7
  NM_010206.1     1,135                              fibroblast growth factor receptor 1
  NM_146035.1     1,122                           mannoside acetylglucosaminyltransferase 2
  NM_175930.2     1,118                        Rap guanine nucleotide exchange factor (GEF) 5
  NM_013819.1     1,111                            histocompatibility 2, M region locus 3
  NM_008666.1     1,094                              myelin transcription factor 1-like
  NM_029823.1     1,092                                  RIKEN cDNA 6530401D17 gene
  NM_172758.1     1,090                                    cDNA sequence BC031853
  AK040457.1      1,085                                interleukin 27 receptor, alpha
  NM_194355.1     1,079                                 spire homolog 1 (Drosophila)
  NM_007881.4     1,072                             dentatorubral pallidoluysian atrophy
  NM_025522.1     1,064                         dehydrogenase/reductase (SDR family) member 7
  NM_008549.1     1,063                                    mannosidase 2, alpha 1
  NM_010545.2     1,058                                 Ia-associated invariant chain
  NM_008810.2     1,058                               pyruvate dehydrogenase E1 alpha 1
  NM_175007.1     1,044                                          amphiphysin
  NM_028270.2     1,029                          aldehyde dehydrogenase 1 family, member B1
  NM_008737.1     1,024                                          neuropilin
  NM_008666.1     1,023                              myelin transcription factor 1-like
  NM_025932.1     1,016                                 synapse associated protein 1
  NM_010195.1     1,006                                 G protein-coupled receptor 49

  DOWNREGULATED:            
  ---------------- -------- ------------------------------------------------------------------------------------------------------------------
  NM_019932.1       −3,893                                           chemokine (C-X-C motif) ligand 4
  NM_010703.2       −2,642                                        **lymphoid enhancer binding factor 1**
  NM_013492.1       −2,293                                                      clusterin
  NM_011702.1       −2,053                                          vasoactive intestinal polypeptide
  NM_010685.2       −1,992                                          lysosomal membrane glycoprotein 2
  NM_011333.1       −1,986                                            chemokine (C-C motif) ligand 2
  NM_010658.2       −1,809                       v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)
  NM_010515.1       −1,705                                        insulin-like growth factor 2 receptor
  AK033214.1        −1,677                                                 G elongation factor
  BC053489.1        −1,557                                             insulin-like growth factor 2
  NM_023422.1       −1,438                                                   histone 1, H2bc
  AK027922.1        −1,427                                          glutathione S-transferase omega 1
  NM_177708.3       −1,420                                             reticulon 4 receptor-like 1
  NM_175395.2       −1,418                                RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene
  NM_053273.1       −1,410                                            tweety homolog 2 (Drosophila)
  NM_009344.1       −1,395                                 pleckstrin homology-like domain, family A, member 1
  NM_011844.3       −1,349                                                 monoglyceride lipase
  NM_009776.1       −1,346                             serine (or cysteine) proteinase inhibitor, clade G, member 1
  NM_021274.1       −1,339                                          chemokine (C-X-C motif) ligand 10
  NM_021897.1       −1,337                            transformation related protein 53 inducible nuclear protein 1
  NM_138683.1       −1,303                                     thrombospondin type 1 domain containing gene
  NM_010789.1       −1,292                                      myeloid ecotropic viral integration site 1
  NM_016867.1       −1,291                                    semaF cytoplasmic domain associated protein 2
  BC058269.1        −1,290                                           RAR-related orphan receptor beta
  NM_007635.2       −1,279                                                      cyclin G2
  NM_015818.1       −1,275                                        heparan sulfate 6-O-sulfotransferase 1
  NM_026416.2       −1,261                                           S100 calcium binding protein A16
  NM_145825.1       −1,260                                                      centrin 4
  AK035160.1        −1,252                              heart and neural crest derivatives expressed transcript 2
  NM_028535.1       −1,251                                              RIKEN cDNA 1700049E17 gene
  AK031672.1        −1,246                                    DNA segment, Chr 11, ERATO Doi 498, expressed
  NM_178405.2       −1,233                                   ATPase, Na+/K+ transporting, alpha 2 polypeptide
  NM_172854.1       −1,213                                              RIKEN cDNA 4932431K08 gene
  NM_009242.1       −1,180                                      secreted acidic cysteine rich glycoprotein
  NM_021537.2       −1,172                                          serine/threonine kinase 25 (yeast)
  NM_008250.1       −1,167                                               H2.0-like homeo box gene
  NM_008538.2       −1,167                                myristoylated alanine rich protein kinase C substrate
  NM_026793.1       −1,166                                                     myc target 1
  NM_011353.1       −1,163                                               small EDRK-rich factor 1
  NM_026358.1       −1,160                                              RIKEN cDNA 4930583H14 gene
  NM_009726.2       −1,158                                     ATPase, Cu++ transporting, alpha polypeptide
  NM_194268.2       −1,155                                           one cut domain, family member 2
  NM_011295.2       −1,142                                                ribosomal protein S12
  NM_175103.2       −1,135                                              RIKEN cDNA 1110025L05 gene
  NM_025836.1       −1,130                                    mannose-6-phosphate receptor binding protein 1
  NM_025692.1       −1,127                                  ubiquitin-activating enzyme E1-domain containing 1
  NM_025394.1       −1,126                            translocase of outer mitochondrial membrane 7 homolog (yeast)
  NM_028279.1       −1,125                                    N-acetylated alpha-linked acidic dipeptidase 2
  NM_133780.2       −1,125                                             translocated promoter region
  NM_013660.1       −1,120   sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
  NM_013692.1       −1,120                                        TGFB inducible early growth response 1
  NM_010357.1       −1,119                                          glutathione S-transferase, alpha 4
  NM_018865.1       −1,108                                      WNT1 inducible signaling pathway protein 1
  NM_010317.2       −1,107                           guanine nucleotide binding protein (G protein), gamma 4 subunit
  NM_173788.2       −1,101                                            natriuretic peptide receptor 2
  NM_175238.4       −1,089                                     DNA segment, Chr 2, ERATO Doi 145, expressed
  NM_011313.1       −1,088                                     S100 calcium binding protein A6 (calcyclin)
  NM_025735.1       −1,080                                 microtubule-associated protein 1 light chain 3 alpha
  NM_178751.2       −1,080                                              RIKEN cDNA A730041O15 gene
  NM_030037.1       −1,078                                           motile sperm domain containing 3
  NM_017367.2       −1,078                                                       cyclin I
  NM_133218.1       −1,077                                            glucocorticoid induced gene 1
  AK010069.1        −1,075                               DNA segment, Chr 7, Wayne State University 87, expressed
  NM_026033.1       −1,074                                          ocular development associated gene
  NM_021398.1       −1,070                                          solute carrier family 43, member 3
  NM_174988.2       −1,063                                                     cadherin 22
  NM_026111.2       −1,043                                              RIKEN cDNA 1810019P04 gene
  NM_012057.1       −1,042                                            interferon regulatory factor 5
  AK076923.1        −1,042                              protein phosphatase 1B, magnesium dependent, beta isoform
  NM_133859.1       −1,040                                                 olfactomedin-like 3
  NM_026565.2       −1,038                                              RIKEN cDNA 9430083G14 gene
  NM_133942.1       −1,037                                             expressed sequence AA960558
  AK003039.1        −1,030                                             glycolipid transfer protein
  NM_008967.1       −1,022                                            prostaglandin I receptor (IP)
  NM_023649.1       −1,020                                          Usher syndrome 1C homolog (human)
  NM_025946.2       −1,013                                              RIKEN cDNA 2010100O12 gene
  NM_009113.2       −1,010                                           S100 calcium binding protein A13
  NM_027285.1       −1,009                                              RIKEN cDNA 1700029I01 gene
  NM_172296.1       −1,009                           doublesex and mab-3 related transcription factor like family A2
  NM_009814.1       −1,007                                                   calsequestrin 2
  NM_013765.1       −1,005                                                ribosomal protein S26
  NM_011952.1       −1,003                                          mitogen activated protein kinase 3
  NM_010831.1       −1,001                                                   SNF1-like kinase

  UPREGULATED:                             
  -------------- ------- ----------------- -------------------------------------------------------------------------------------------
  NM_007990.1     3,603         Fau         Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived)
  NM_133198.1     2,620        Pygl                                       liver glycogen phosphorylase
  NM_019703.2     2,343        Pfkp                                       phosphofructokinase, platelet
  NM_007407.2     2,294      Adcyap1r1                        adenylate cyclase activating polypeptide 1 receptor 1
  NM_025703.2     2,270    3930402F23Rik                                   RIKEN cDNA 3930402F23 gene
  NM_183271.1     2,215    1700049M11Rik                                   RIKEN cDNA 1700049M11 gene
  BC053970.1      2,198       Ndufab1                      NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
  NM_130888.1     2,106        Nxf7                                        nuclear RNA export factor 7
  D87975.1        2,052      Serpinf1                     serine (or cysteine) proteinase inhibitor, clade F, member 1
  NM_021389.3     1,966       Sh3kbp1                                  SH3-domain kinase binding protein 1
  NM_054095.1     1,910       Efcbp2                                    EF hand calcium binding protein 2
  NM_133362.1     1,797        Erdr1                                  erythroid differentiation regulator 1
  NM_177752.2     1,682     6820428D13                                   hypothetical protein 6820428D13
  NM_172960.1     1,608        Adck5                                     aarF domain containing kinase 5
  AK040457.1      1,501       Il27ra                                     interleukin 27 receptor, alpha
  NM_008595.1     1,446        Mfng                                     manic fringe homolog (Drosophila)
  NM_033325.1     1,445        Loxl2                                          lysyl oxidase-like 2
  NM_145526.1     1,425        P2rx3                          purinergic receptor P2X, ligand-gated ion channel, 3
  NM_008183.2     1,419        Gstm2                                     glutathione S-transferase, mu 2
  NM_025695.2     1,414       Smc6l1                       SMC6 structural maintenance of chromosomes 6-like 1 (yeast)
  NM_009369.1     1,414        Tgfbi                                transforming growth factor, beta induced
  NM_025522.1     1,410        Dhrs7                              dehydrogenase/reductase (SDR family) member 7
  NM_007997.1     1,399        Fdxr                                           ferredoxin reductase
  NM_207204.1     1,382    4930519N13Rik                                   RIKEN cDNA 4930519N13 gene
  NM_007833.1     1,360         Dcn                                                  decorin
  NM_008877.2     1,342         Plg                                              **plasminogen**
  NM_019966.1     1,331        Mlycd                                        malonyl-CoA decarboxylase
  NM_175027.2     1,316      BC022692                                        cDNA sequence BC022692
  NM_080553.1     1,309        Itpr3                                 inositol 1,4,5-triphosphate receptor 3
  NM_010480.4     1,308        Hspca                                       heat shock protein 1, alpha
  NM_029823.1     1,273    6530401D17Rik                                   RIKEN cDNA 6530401D17 gene
  NM_008144.3     1,273        Bscl2                      Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)
  NM_198031.1     1,266       Tubgcp3                              tubulin, gamma complex associated protein 3
  NM_008810.2     1,249        Pdha1                                    pyruvate dehydrogenase E1 alpha 1
  NM_008666.1     1,246        Myt1l                                   myelin transcription factor 1-like
  NM_173427.1     1,240    B230308G19Rik                                   RIKEN cDNA B230308G19 gene
  NM_178794.2     1,234      U2af1-rs2          U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1, related sequence 2
  NM_146034.1     1,234        Mgea6                        meningioma expressed antigen 6 (coiled-coil proline-rich)
  NM_019552.1     1,229       Abcb10                         ATP-binding cassette, sub-family B (MDR/TAP), member 10
  NM_178915.2     1,221      AI839735                                      expressed sequence AI839735
  NM_008243.2     1,215        Mst1                         macrophage stimulating 1 (hepatocyte growth factor-like)
  NM_145482.1     1,175        ORF21                                          open reading frame 21
  NM_025936.1     1,173        Rars                                          arginyl-tRNA synthetase
  NM_028262.1     1,168     D12Ertd771e                           DNA segment, Chr 12, ERATO Doi 771, expressed
  NM_031174.2     1,164        Dscam                                  Down syndrome cell adhesion molecule
  NM_023304.1     1,149        Fgf22                                       fibroblast growth factor 22
  NM_025932.1     1,139        Syap1                                      synapse associated protein 1
  NM_013778.1     1,130   Akr1c13;Akr1c12       aldo-keto reductase family 1, member C13;aldo-keto reductase family 1, member C12
  NM_013819.1     1,129        H2-M3                                 histocompatibility 2, M region locus 3
  NM_007407.2     1,126      Adcyap1r1                        adenylate cyclase activating polypeptide 1 receptor 1
  NM_021273.2     1,122         Ckb                                          creatine kinase, brain
  NM_008033.2     1,119        Fnta                                   farnesyltransferase, CAAX box, alpha
  NM_009529.1     1,115         Xmr                                      Xlr-related, meiosis regulated
  NM_207269.1     1,111    D330050I23Rik                                   RIKEN cDNA D330050I23 gene
  NM_010752.1     1,108       Mad1l1                                    mitotic arrest deficient 1-like 1
  NM_028089.1     1,091       Cyp2c55                        cytochrome P450, family 2, subfamily c, polypeptide 55
  NM_133224.1     1,090       Atp13a                                             ATPase type 13A
  NM_025656.1     1,089        Sip1                          survivor of motor neuron protein interacting protein 1
  NM_028002.1     1,088    2310069P03Rik                                   RIKEN cDNA 2310069P03 gene
  NM_010724.1     1,086        Psmb8                          proteosome (prosome, macropain) subunit, beta type 8
  NM_028131.1     1,081    2610510J17Rik                                   RIKEN cDNA 2610510J17 gene
  NM_009239.1     1,080         Sp4                                    trans-acting transcription factor 4
  NM_025437.2     1,077       Eif1ay                          eukaryotic translation initiation factor 1A, Y-linked
  NM_183294.1     1,072        Cdkl1                          cyclin-dependent kinase-like 1 (CDC2-related kinase)
  NM_013779.1     1,070       Magel2                                      melanoma antigen, family L, 2
  NM_021556.2     1,063       Mrps30                                   mitochondrial ribosomal protein S30
  NM_207210.1     1,059        Dyrk4                    dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4
  NM_146035.1     1,057        Mgat2                                mannoside acetylglucosaminyltransferase 2
  NM_144844.1     1,049        Pcca                            propionyl-Coenzyme A carboxylase, alpha polypeptide
  NM_178389.2     1,045        Gale                                        galactose-4-epimerase, UDP
  NM_012035.1     1,041        Trpc7                   transient receptor potential cation channel, subfamily C, member 7
  NM_176953.2     1,034        Lig4                                       ligase IV, DNA, ATP-dependent
  NM_008183.2     1,033        Gstm2                                     glutathione S-transferase, mu 2
  NM_178242.2     1,032       Zfp469                                         zinc finger protein 469
  NM_009933.1     1,030       Col6a1                                      procollagen, type VI, alpha 1
  NM_010068.1     1,030       Dnmt3b                                        DNA methyltransferase 3B
  NM_028270.2     1,027       Aldh1b1                              aldehyde dehydrogenase 1 family, member B1
  NM_172783.1     1,022        Phka2                                      phosphorylase kinase alpha 2
  NM_008590.1     1,020        Mest                                       mesoderm specific transcript
  NM_013761.2     1,017         Srr                                              serine racemase
  NM_029541.1     1,017    6530401D17Rik                                   RIKEN cDNA 6530401D17 gene
  NM_025486.1     1,012    1700006C06Rik                                   RIKEN cDNA 1700006C06 gene
  NM_130864.2     1,012        Acaa1                                   acetyl-Coenzyme A acyltransferase 1

  DOWNREGULATED:                                           
  ---------------- -------- ------------------------------ --------------------------------------------------------------------------------------------------------------------------
  NM_019932.1       −3,616              Cxcl4                                                           chemokine (C-X-C motif) ligand 4
  NM_010703.2       −3,395               Lef1                                                        **lymphoid enhancer binding factor 1**
  NM_011702.1       −2,102               Vip                                                           vasoactive intestinal polypeptide
  NM_010685.2       −2,085              Lamp2                                                          lysosomal membrane glycoprotein 2
  NM_011333.1       −1,843               Ccl2                                                            chemokine (C-C motif) ligand 2
  AK027922.1        −1,770              Gsto1                                                          glutathione S-transferase omega 1
  NM_010515.1       −1,748              Igf2r                                                        insulin-like growth factor 2 receptor
  NM_007635.2       −1,679              Ccng2                                                                      cyclin G2
  NM_013492.1       −1,634               Clu                                                                       clusterin
  NM_027285.1       −1,585          1700029I01Rik                                                          RIKEN cDNA 1700029I01 gene
  NM_177708.3       −1,583             Rtn4rl1             
  NM_016867.1       −1,571             Semcap2                                                   semaF cytoplasmic domain associated protein 2
  NM_009150.2       −1,552        Selenbp2;Selenbp1                                          selenium binding protein 2;selenium binding protein 1
  NM_177820.2       −1,484          9130218O11Rik                                                          RIKEN cDNA 9130218O11 gene
  NM_009726.2       −1,423              Atp7a                                                     ATPase, Cu++ transporting, alpha polypeptide
  NM_026416.2       −1,393             S100a16                                                          S100 calcium binding protein A16
  NM_023422.1       −1,390            Hist1h2bc                                                                 histone 1, H2bc
  NM_009760.2       −1,378              Bnip3                                                BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3
  NM_030037.1       −1,334              Mospd3                                                          motile sperm domain containing 3
  NM_010149.2       −1,323               Epor                                                               erythropoietin receptor
  NM_172296.1       −1,305              Dmrta2                                          doublesex and mab-3 related transcription factor like family A2
  AK076923.1        −1,305              Ppm1b                                              protein phosphatase 1B, magnesium dependent, beta isoform
  NM_026030.1       −1,298              Eif2s2                                            eukaryotic translation initiation factor 2, subunit 2 (beta)
  NM_194268.2       −1,294             Onecut2                                                          one cut domain, family member 2
  NM_008926.2       −1,293              Prkg2                                                       protein kinase, cGMP-dependent, type II
  NM_026565.2       −1,291          9430083G14Rik                                                          RIKEN cDNA 9430083G14 gene
  NM_025949.1       −1,279             Rps6ka6                                                     ribosomal protein S6 kinase polypeptide 6
  NM_009242.1       −1,264              Sparc                                                      secreted acidic cysteine rich glycoprotein
  NM_178405.2       −1,256              Atp1a2                                                  ATPase, Na+/K+ transporting, alpha 2 polypeptide
  NM_007874.2       −1,237               Dp1                                                                 deleted in polyposis 1
  NM_026793.1       −1,236              Myct1                                                                     myc target 1
  NM_177603.1       −1,228              Frat2                                                 frequently rearranged in advanced T-cell lymphomas 2
  NM_025836.1       −1,224             M6prbp1                                                   mannose-6-phosphate receptor binding protein 1
  NM_028535.1       −1,224          1700049E17Rik                                                          RIKEN cDNA 1700049E17 gene
  NM_026358.1       −1,221          4930583H14Rik                                                          RIKEN cDNA 4930583H14 gene
  NM_172132.1       −1,218              Jmjd2b                                                            jumonji domain containing 2B
  AK005820.1        −1,210              Rabl5                                                      RAB, member of RAS oncogene family-like 5
  AK049314.1        −1,193              Trim27                                                            tripartite motif protein 27
  NM_017367.2       −1,188               Ccni                                                                       cyclin I
  NM_009814.1       −1,180              Casq2                                                                   calsequestrin 2
  NM_009101.1       −1,174               Rras                                                       Harvey rat sarcoma oncogene, subgroup R
  AK003039.1        −1,174               Gltp                                                             glycolipid transfer protein
  NM_008467.2       −1,172              Kpna4                                                            karyopherin (importin) alpha 4
  BC038145.1        −1,172             BC002199                                                              cDNA sequence BC002199
  NM_133780.2       −1,168               Tpr                                                              translocated promoter region
  NM_177798.3       −1,157               Frs2                                                    fibroblast growth factor receptor substrate 2
  NM_008906.2       −1,153               Ppgb                                                      protective protein for beta-galactosidase
  NM_015818.1       −1,152              Hs6st1                                                       heparan sulfate 6-O-sulfotransferase 1
  NM_009113.2       −1,152             S100a13                                                          S100 calcium binding protein A13
  NM_009344.1       −1,148              Phlda1                                                pleckstrin homology-like domain, family A, member 1
  NM_019675.2       −1,148              Stmn4                                                                   stathmin-like 4
  NM_146141.1       −1,147          1110013G13Rik                                                          RIKEN cDNA 1110013G13 gene
  NM_009140.1       −1,146              Cxcl2                                                           chemokine (C-X-C motif) ligand 2
  NM_173788.2       −1,145               Npr2                                                            natriuretic peptide receptor 2
  NM_021274.1       −1,144              Cxcl10                                                         chemokine (C-X-C motif) ligand 10
  AK052456.1        −1,142          D430026P16Rik                                                          RIKEN cDNA D430026P16 gene
  NM_153399.1       −1,140              Syne1                                                             synaptic nuclear envelope 1
  NM_011756.3       −1,136              Zfp36                                                                zinc finger protein 36
  AK083556.1        −1,136               Fst                                                                      follistatin
  NM_026033.1       −1,122               Odag                                                          ocular development associated gene
  NM_031997.2       −1,121              Tmem2                                                               transmembrane protein 2
  NM_178772.2       −1,117          B230106I24Rik                                                          RIKEN cDNA B230106I24 gene
  NM_011353.1       −1,112              Serf1                                                               small EDRK-rich factor 1
  NM_021398.1       −1,110             Slc43a3                                                         solute carrier family 43, member 3
  NM_027482.1       −1,095          5730508B09Rik                                                          RIKEN cDNA 5730508B09 gene
  NM_133777.1       −1,087              Ube2s                                                           ubiquitin-conjugating enzyme E2S
  NM_012057.1       −1,083               Irf5                                                            interferon regulatory factor 5
  NM_013660.1       −1,080              Sema4d                                              sema domain, immunoglobulin domain (Ig), (semaphorin) 4D
  NM_146260.1       −1,080               Tmie                                                               transmembrane inner ear
  NM_153068.1       −1,075               Ehd2                                                                EH-domain containing 2
  NM_138584.1       −1,074              Spg21                                                        spastic paraplegia 21 homolog (human)
  NM_011295.2       −1,073              Rps12                                                                ribosomal protein S12
  NM_030696.2       −1,071             Slc16a3                                       solute carrier family 16 (monocarboxylic acid transporters), member 3
  NM_130903.2       −1,068              Cd209c                                                                   CD209c antigen
  NM_020586.1       −1,068          5031400M07Rik                                                          RIKEN cDNA 5031400M07 gene
  NM_031997.2       −1,067              Tmem2                                                               transmembrane protein 2
  NM_010789.1       −1,065              Meis1                                                      myeloid ecotropic viral integration site 1
  NM_011498.2       −1,065              Bhlhb2                                                 basic helix-loop-helix domain containing, class B2
  NM_025290.2       −1,063              Tsga2                                                               testis specific gene A2
  NM_139144.2       −1,063               Ogt                O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)
  NM_009895.2       −1,059               Cish                                                      cytokine inducible SH2-containing protein
  NM_011171.1       −1,057              Procr                                                           protein C receptor, endothelial
  NM_019880.2       −1,056              Mtch1                                                     mitochondrial carrier homolog 1 (C. elegans)
  NM_010658.2       −1,056               Mafb                                       v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)
  NM_011046.1       −1,054              Furin                                                   furin (paired basic amino acid cleaving enzyme)
  NM_011252.2       −1,053               Rbmx                                                       RNA binding motif protein, X chromosome
  NM_007585.2       −1,047              Anxa2                                                                      annexin A2
  NM_025348.1       −1,045              Ndufa3                                               NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
  BC028655.1        −1,044               Solt                                                 SoxLZ/Sox6 leucine zipper binding protein in testis
  NM_028279.1       −1,043             Naalad2                                                   N-acetylated alpha-linked acidic dipeptidase 2
  NM_018865.1       −1,040              Wisp1                                                      WNT1 inducible signaling pathway protein 1
  NM_178751.2       −1,038          A730041O15Rik                                                          RIKEN cDNA A730041O15 gene
  NM_029688.2       −1,037               Npn3                                                               neoplastic progression 3
  NM_013692.1       −1,031              Tieg1                                                        TGFB inducible early growth response 1
  NM_013525.1       −1,025               Gas5                                                               growth arrest specific 5
  NM_175395.2       −1,023   1700001A24Rik; 6330578E17Rik                                    RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene
  NM_019704.1       −1,023              C78915                                                             expressed sequence C78915
  NM_010234.2       −1,022               Fos                                                               FBJ osteosarcoma oncogene
  NM_011594.2       −1,020              Timp2                                                       tissue inhibitor of metalloproteinase 2
  NM_198420.1       −1,019            D15Wsu169e                                           DNA segment, Chr 15, Wayne State University 169, expressed
  NM_008662.1       −1,018               Myo6                                                                      myosin VI
  AK033214.1        −1,018               Gfm                                                                  G elongation factor
  NM_010885.2       −1,013              Ndufa2                                               NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2
  NM_027287.1       −1,007              Dnajb4                                                    DnaJ (Hsp40) homolog, subfamily B, member 4
  NM_133942.1       −1,006             AA960558                                                           expressed sequence AA960558
  NM_007664.1       −1,005               Cdh2                                                                      cadherin 2
  NM_027189.1       −1,004              Gemin7                                                    gem (nuclear organelle) associated protein 7
  NM_009627.1       −1,001               Adm                                                                     adrenomedullin

This Table represent a selection of annotated genes upregulated (red) and downregulated (green) by estradiol, sensitive to LEF-1 mutant. The list contains only those "annotated genes" with a log2R higher or lower than 1. **A** represent the control cell line (N2a-m-*mock transfected*). **B** represents the cell line transfected with *delta-56*-LEF-1. In the table **es**t, represents treatment with estradiol; and **Wnt**, treatment with Wnt3a.

We labeled two genes (***plasminogen*** **and** ***LEF-1***) regulated by estradiol or by Wnt3a , both were subsequently validated at protein level.

As shown in [figure 9A](#pone-0005153-g009){ref-type="fig"}, the log~2~ R of some of these genes was low, and certainly, the protein expression showed no differences. Considering that the low level of detection may be related with the short exposure time (60 minutes), we extended the treatment to confirm the differential regulation of some genes mediated by Δ56LEF-1. Accordingly, we treated the cell lines with estradiol or Wnt3a over a period of 24 h to allow for the accumulation of the protein. Soluble fraction, or nuclear fractions, or conditioned medium was obtained from treated cells and we analyzed the genes identified as differentially expressed in the microarray (when antibodies were available) as well as some genes known to be regulated by Wnt, such as E-cadherin, β-catenin or cyclin D.

Our data confirmed some of the variations in the genes described. Interestingly, MMP-2 secretion was most prominent in Wnt-treated cells whereas the proactive form appeared to be secreted prominently by Δ56LEF-1/N2a-m cells. Similarly, β-catenin displayed weaker protein expression in Δ56LEF-1/N2a-m cells, independently of the treatment.

Finally, a second set of genes were found, those that respond to estradiol (and/or Wnt) in control cells and whose regulation was modified by the presence of Δ56LEF-1. Indeed, longer treatment enabled clear differences to be detected at the protein level in genes such as N-cadherin and Cyclin D2. Our data indicated that N-cadherin was upregulated by estradiol and Wnt, and that the expression of Δ56LEF-1 almost completely blocked these effects ([Figure 9B](#pone-0005153-g009){ref-type="fig"}). While Cyclin D2 behaved similarly, Cyclin D1 appeared to be unchanged and unaffected by treatments ([Figure 9B](#pone-0005153-g009){ref-type="fig"}). On the other hand, E-cadherin was upregulated by estradiol in control cells (Group **A**), whereas the presence of Δ56LEF-1 generated an uncontrolled upregulation. This result revealed an important role for LEF-1 in estrogen-regulated E-cadherin expression.

Discussion {#s3}
==========

Estrogens may act through different mechanisms, the best known of which involves their capacity to directly bind to and dimerize estrogen receptors (ERs). This hormone-protein complex can either bind directly to promoter estrogen response elements (EREs), or act as a cofactor at non-ERE sites through the interaction with other DNA-binding elements, such as AP-1, or c-Jun [@pone.0005153-Beato1], [@pone.0005153-Tora1]--[@pone.0005153-Truss1]. A second mode of action is associated with the so-called "non genomic" or "rapid" actions, that include the activation of PKC, G-protein-coupled receptors, ERKs and PI3K/Akt in different cell systems [@pone.0005153-Singh1], [@pone.0005153-Yu1]. Regarding this theme, we recently reported that ERα forms a protein complex with GSK3 and β-catenin in the hippocampus of ovariectomized rats; the action of estradiol dissociated β-catenin from the complex in a manner that was clearly correlated with the inhibition of GSK3 [@pone.0005153-CardonaGomez1]. The interaction of ERα with GSK3 does not appear to be specific for neurons and indeed, it has recently been demonstrated that ERα is also phosphorylated and modulated by GSK3 in other cell types [@pone.0005153-Kouzmenko1].

Estradiol, through a "rapid response", activated the pathway Akt/GSK3, stabilized β-catenin, and modulates TCF-mediated transcription, in neurons {#s3a}
-------------------------------------------------------------------------------------------------------------------------------------------------

We had initially found that the inhibition of GSK3 by estradiol was correlated with the stabilization of β-catenin. Thus, our first aim here was to determine whether the pool of β-catenin regulated by estradiol acts as a co-transcriptional modulator using canonical TCF-mediated transcription or alternatively, whether the stabilization of β-catenin plays some other role. With this aim, we selected a neuronal cell line easily amenable to transfection with a TCF-reporter: the N2a-m cell line which expresses the α and β ER receptors and accumulates nuclear ER when treated with estradiol. Significantly, we detected a complex of β-catenin and GSK3 in these cells following exposure to either ERα or ERβ. When N2a-m or cortical neurons were treated with estradiol, we detected a similar biochemical response with an increase of GSK3 serine phosphorylation as well as the stabilization of β-catenin. This inhibition of GSK3 was time- and concentration-dependent, and these data are in essence similar to those described in the hippocampus of ovariectomiced rats after estradiol treatment, or in hippocampal neurons [@pone.0005153-CardonaGomez1].

Taking into account these initial results, the question arose as to whether β-catenin stabilized by estradiol might modulate transcription. It is believed that β-catenin has two different and complementary roles in cells; it may contribute to the cell-cell adhesion or it may act as a co-transcriptional regulator of the TCF family [@pone.0005153-Moon1]--[@pone.0005153-Barolo1]. Our data first showed that estradiol activated TCF-mediated transcription at concentrations of 10×10^−9^ M. This nuclear activation of *luciferase* was time- and concentration-dependent, it was maximal at 10--20×10^−8^ M, and it could be abolished by the ER antagonist ICI 182780. Similar, but slightly weaker transcriptional activation could be obtained with the ERα-selective agonist, PPT (5--10 nM), as well with the ERβ-selective agonist, DPN (5--10 nM). All these data strongly suggested that estradiol stabilizes β-catenin through ERα and ERβ, and that at least a portion of this protein pool can activate transcription. This transcriptional activation depended on the phosphorylation status of β-catenin. Indeed, the highest levels of transcription were obtained with a mutated form of β-catenin (S33Y) that was virtually unaffected by estradiol. These data raise the question as to whether this TCF- β-catenin mediated transcription is similar to that obtained with Wnt proteins.

We have also showed that estradiol may activate transcription from a portion of the *engrailed-1* promoter that contains well characterized TCF elements (pENP1-*luc*) (McGrew et al. 1999), and also activate transcription in primary neurons derived from mice transgenic for a TCF-β-galactosidase reporter driving the expression of a *luciferase* reporter. It is important to remember that the estradiol-dependent transcription mediated by pENP1-*luc* is severely inhibited by the expression a LEF-1 truncated-mutant (Δ56LEF-1) [@pone.0005153-Hsu1]. We found that estradiol slightly augmented the formation of DNA-TCF complexes, a similar effect to that produced by exposure to Wnt3a. This transcriptional activation is dependent on LEF-1, since antibodies against LEF-1 can disrupt DNA-complex formation. Furthermore, the presence of Δ56LEF-1 almost completely prevented estradiol-mediated transcription.

It was recently demonstrated that estradiol regulates LEF-1 and Tcf3, and more importantly, that a complex containing ERα and Tcf3/LEF-1 may be immunoprecipitated from mouse uterus extracts [@pone.0005153-Ray1]. Accordingly, it was proposed that a complex composed of ERα/β-catenin/Tcf-3 is an important part of the estradiol response in this tissue. Although we cannot completely rule out this possibility (particularly since we did not use the same methodology), in our experiments LEF-1 was not immunoprecipitated when antibodies against either ERα or β were used. Only antibodies against LEF-1 prevented the formation of a DNA-protein complex in EMSA assays, unlike antibodies against Tcf 3 or ERα. Indeed, the initial cytoplasmic ERα/β-catenin/GSK3 complex appears to be different, with the complex in uterus being arranged (assembled?) after hormone addition, while in neural cells and neurons the complex is detected even prior to hormone treatment.

Further studies will be required to clarify whether the same ERα/β-catenin/Tcf-3 complex observed in the uterus is also present in neurons or in some specific brain regions. It will be interesting analyzing other possible components that might mediate the effect of the estrogen receptor on TCF/LEF-1 transcription, such as transducin beta-like protein 1 (TBL1) and its highly related family member TBLR1 [@pone.0005153-Li1]; among many others (see reviewed in [@pone.0005153-Moon1]--[@pone.0005153-Barolo1]). A different point worthy of mention is that we detected multiple ERα bands in N2A cell extracts and after estradiol treatment only some of them appear to move into the nuclear fraction. This observation opens some interesting questions about the molecular nature of these multiple bands and why only some of them are mobilized. We are currently initiating the study of these ERα isoform/s in order to clarify the different possibilities suggested by the bibliography (isoform *versus* proteolysis??) [@pone.0005153-Flouriot1]--[@pone.0005153-Metivier1].

Several publications have recently emerged in which new elements have been described that regulate the Wnt-β-catenin pathway. For example, c-Jun forms a complex with β-catenin and Dvl in the nucleus, and this association regulates the transcriptional activity of β-catenin [@pone.0005153-Gan1]. Moreover, Rac1-JNK2 appears to act as a novel modulator of β-catenin mediated transcription [@pone.0005153-Wu1]. Thus, the complex regulation of β-catenin is becoming more evident, as it is not only modulated through its cellular distribution or phosphorylation, but also by the proteins with which it associates. Here, we describe a novel pathway that regulates β-catenin/TCF activity through a ligand, estradiol, using at least some of the components of the original Wnt pathway.

Is the gene expression through LEF-1/β-catenin estradiol-mediated similar to those triggered by Wnt? {#s3b}
----------------------------------------------------------------------------------------------------

To determine more specifically whether estradiol can regulate gene expression using the TCF/LEF-1-β-catenin system in a way similar to that of Wnt3a, we generated N2a-m cells stably transfected with Δ56LEF-1 cDNA. By analyzing the gene expression profile of these cell lines on an Aplied Biosystems Mouse Genome Survey Microarray, we detected 223 genes modified by estradiol; whereas Wnt3a modified 303 genes, sensitive to Δ56LEF-1 (see [**Table 1**](#pone-0005153-t001){ref-type="table"}, containing only the annotated sequences).

To validate these changes, at the protein level, we had to extend the treatment period and as a result, we selected some representative genes from our array, such as *Plg* as well as some genes that have been previously associated with Wnt stimuli, such as E-Cadherin [@pone.0005153-Jamora1], Cyclin D [@pone.0005153-Shtutman1]--[@pone.0005153-Sansom1], c-myc [@pone.0005153-He1], LEF-1 [@pone.0005153-Hovanes1]--[@pone.0005153-Filali1] and TCF-1 [@pone.0005153-Roose1]. We used commercially available antibodies to validate the changes in the levels of these proteins in the presence of Δ56LEF-1 and/or the hormone or Wnt. Our data revealed two major types of response: first, those genes modified initially by the LEF-1 mutant background, such as Plasminogen, LEF-1 , β-catenin and MMP-2, and second, a group of genes which initially responded to estradiol, either positively or negatively, and additionally showed an increased response in the Δ56LEF-1 cells, such as N-Cadherin, E-Cadherin and Cyclin D2. Indeed, the CyclinD2 promoter is clearly regulated by the estrogen receptor as well as by TCFs, although its responsiveness to Wnt proteins has also been assessed [@pone.0005153-Shtutman1], [@pone.0005153-Sansom1]. Our data indicate that in neurons, this gene may be regulated by both elements, at least in part *via* β-catenin/LEF-1.

Taken together, these data demonstrate the existence of a new pathway controlled by estradiol, at least in neurons. Our data show that this pathway contains some elements that may belong to the canonical Wnt-pathway. Indeed some reports indicate that estradiol may control the response of the Wnt pathway as an important part of its neuroprotective role. This neuroprotective response is mediated by increase of Wnt3a and inhibition of Dkk1 elevation, triggered after cerebral ischemia [@pone.0005153-Zhang1]. More work is now required to identify whether a similar mechanism is specific for certain types of brain insults or represents a more general mechanism. The analysis of our arrays ([**Table 1**](#pone-0005153-t001){ref-type="table"}) supports the hypothesis that only part of the estradiol response sensitive to LEF-1, is similar to Wnt3a response sensitive to LEF-1. This open the possibility that in addition of collaborate with the Wnt response, estradiol may regulated a pool genes (β-catenin/LEF-1- directed), independently of Wnt status.

"Neuroprotective role" of estradiol and GSK3 inhibition {#s3c}
-------------------------------------------------------

A complementary and important aspect of our data is that estradiol modulates the kinase activity of GSK3 irrespective of the neuronal source, and consequently the stabilization of β-catenin is an important event in these so called "non-genomic actions". When considering the role of GSK3 and β-catenin in neurodegeneration [@pone.0005153-Lucas1], such as in relation to Alzheimer\'s disease or ischemia, some of the functional effects of estradiol may, at least in part, represent an important physiological control of this kinase [@pone.0005153-Xu1]. We have to remember that in model systems of β-amyloid-mediated toxicity, similar concentrations of estradiol may protect neurons [@pone.0005153-Xu1], [@pone.0005153-McCullough1], [@pone.0005153-Quintanilla1].

Estrogens play an important role in normal brain development [@pone.0005153-ToranAllerand1], [@pone.0005153-Belcher1]. In addition, this hormone appears to exert a more general neuroprotective effect such as in mouse models of Parkinson\'s disease [@pone.0005153-Miller1]--[@pone.0005153-Morissette1] or after brain ischemia [@pone.0005153-Culmsee1]--[@pone.0005153-Simpkins1]. In some ischemia models the estradiol--mediated GSK3 response, appears to be JNK-Dkk1-dependent [@pone.0005153-Zhang1], and we cannot discard this possibility in our neuronal system. However, our data indicate that the estradiol-mediated inhibition of GSK3 is PI3K-Akt dependent (O. Varea et al., unpublished data). It will be very important to determine whether the response that we observed is specific to "immature neurons" or whether it represents a more general mechanism.

Materials and Methods {#s4}
=====================

Primary Cortical neurons and Neuroblastoma N2a-m {#s4a}
------------------------------------------------

Mice were treated following the guidelines of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. In addition all protocols were approved by the institutional animal care and use committee. Cortical neurons were obtained from E18 mouse embryos after isolating the cortex in Ca^2+^- and Mg^2+^-free Hanks Buffer Salt Solution (HBSS 1×, GIBCO). Once 8--10 embryonic cortices were obtained, they were finely cited, washed twice in HBSS 1× buffer,and incubated in 0.25% trypsin (GIBCO) and 1 mg/ml DNAse (Roche) for 15 min at 37°C. Trypsin and DNAse were then eliminated by washing three times, with HBSS 1×, and the cut tissue was then triturated using a siliconized pipette. The cells were counted and plated in a poly-lysine coated (1 mg/ml, Sigma) 60 mm dish containing plating medium (MEM, 20% Glucose, horse serum and antibiotics). After 3 hours plating, the medium was changed to phenol red-free Neurobasal medium supplemented with B-B27 GIBCO) and the neurons were maintained under these conditions for 2 days. Murine neuroblastoma N2a-m cells were grown at 37°C in 7% CO~2~, in DMEM supplemented with 10% fetal calf serum (GIBCO) and 2 mM glutamine.

### Cell treatments {#s4a1}

One day before treatment, the medium was changed to serum and phenol red free-medium The compounds used for treatments were: 17-β-estradiol (stored in ethanol at a concentration of 1 mM), ICI 182780 (Tocris, stored in dimethyl sulfoxide -DMSO- at 2 mM), Wnt3a recombinant protein (R&D systems, dissolved in PBS-BSA 0.1% and stored at 0.1 µg/µl), and the estrogen receptor agonists, 4,4′,4″-(propyl-\[(1)H\]-pyrazole-1,3,5-triyl) trisphenol (PPT, α-selective) and 2,3-bis (4-hydroxyphenyl) propionitrile (DPN (β-selective) agonists, both dissolved in ethanol. Different concentrations of these compounds were used as indicated for each experiment and the controls received the vehicle of each compound alone, ethanol in the case of estradiol, DMSO for ICI 182780 and PBS-BSA 0.1% as control for Wnt3a. The final concentration of ICI 182780 used was depending on the concentration of estradiol, in a ICI/estradiol ratio of 100 times.

Western Blotting and Antibodies {#s4b}
-------------------------------

After two washes with PBS, cell extracts were prepared in lysis buffer containing 200 mM Hepes pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM Na~3~VO~4~, 5 mM EDTA, 1% Triton and a protease inhibitor cocktail (Roche). The cells were left for 30 min on ice in this lysis buffer and then collected with a cell scraper. After adding loading buffer, the samples were boiled for 10 min and resolved by Tris/Glycine SDS-Polyacrylamide gel electrophoresis, and the proteins were then transferred to a nitrocellulose membrane (Amersham) in the presence of 20% methanol and 0.1% SDS. Non-specific signals were blocked by incubating the membrane in PBS-Tween-20 (PBT) and 5% milk for 2 h. The antibodies used to probe the membranes were raised against: Ct ERα 1∶800 (MC-20, Santa Cruz), ERβ 1∶1000 (H-150, Santa Cruz), GSK3 α/β 1∶1000 (Cell signalling), GSKPSer^9,\ 21^ 1∶1000 (Cell Signalling), β-catenin 1∶800 (Transduction Labs), non-phospho β-catenin 1∶800 (Upstate), actin 1∶2000 (Sigma), LEF-1 HMG box 1∶800 (Sigma), cyclin D1 1∶1000 (Santa Cruz), cyclin D2 1∶1000 (MBL), N cadherin 1∶1000 (Sigma), E cadherin 1∶800 (Santa Cruz), MMP2 1∶200 (Santa Cruz), nucleolin 1∶1000 (Santa Cruz), beta-galactosidase (ICN Biomed-Cappel), β-III tubulin (Chemicon). These antibodies were then detected with horseradish peroxidase conjugated secondary antibodies (Amersham) used at a dilution of 1∶5000.

Immunocytochemistry {#s4c}
-------------------

To study the localization of proteins by immunocytochemistry, we fixed cells plated at low density with 4% paraformaldehyde for 20 min at RT. After 3 washes for 10 min in PBS, fixed-cells were incubated with 50 mM NH~4~Cl and then blocked and permeabilized for 30 min with 1% fetal calf serum and 0.1% Triton-X-100 in PBS. The cells were incubated with the primary antibodies for 2 h at RT and after 3 washes with blocking solution, the secondary Alexa fluor-488 or 594 antibodies were added (1∶1000, Molecular Probes). The primary antibodies used were raised against β-catenin (1∶400, Transduction Labs) or ERα (1∶500, MC-20, Santa Cruz). To visualize the distribution of polymerized actin, fixed cells were stained with phalloidin conjugated to Alexa 488 or 594, as indicated in each experiment (1∶100, Molecular Probes). Coverslips were mounted with Fluoromount G (Southern Biotechnology Associates, Inc) and photographs were taken on a confocal microscope (LSM 510 META, Zeiss).

Plasmids and Transient expression in N2a-m cells {#s4d}
------------------------------------------------

The plasmids used for transient expression were: pTOPFlash (Upstate), containing three copies of the consensus sequence recognized by the TCF/LEF transcription factors (CCTTTGATC) and with the c-Fos promoter driving the expression of luciferase gene; pFOPFlash (Upstate) that contains three non-functional copies of the TCF/LEF binding site (CCTTTGGCC); and EGFP-N1 encodes an enhanced green-fluorescent protein used to quantify the efficiency of transfection when co-transfected with TOP/FOPFlash. N2a-m cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer\'s instructions. For transfection, 600,000 cells were plated in a 60 mm-culture dish with growth medium and the day before transfection, the medium was changed to DMEM without FCS or antibiotics. Co-transfections were performed with 2 µl LipofectAMINE (Invitrogen) and 1 µg of total-DNA (0.75 µg TOP/FOP plus 0.25 µg EGFP-N1). After transfection, the medium was changed to DMEM without phenol red or FCS, supplemented with an antibiotic cocktail. Treatments were started 48 h after transfection to coincide with the maximum expression levels of the co-transfected proteins.

Other plasmids used for transfection were: empty pcDNA3 as an internal control; Δ45 β-catenin, a deleted form of β-catenin lacking the N-terminal (kindly provided by Dr. R. Moon); and LEF-1Δ56 (kindly provided by Dr. R. Grosschedl) that expresses a form of LEF-1 that is unable to interact with β-catenin.

Primary Cortical Neuron Nucleofection {#s4e}
-------------------------------------

The TOPFlash plasmid was introduced into cortical neurons by nucleofection (Basic Nucleofector Kit for Primary Mammalian Neural cells, Amaxa Bioscience) according to the manufacturer instructions. A total of 3 µg TOPFlash plus 1 µg GFP was introduced into 4×10^6^ cells, and both luciferase activity and the efficiency of nucleofection were analyzed after 2 days in culture.

Assay of luciferase activity {#s4f}
----------------------------

After treatment of the TOPFlash transfected N2a-m cells, they were incubated in 60 mm plate with 1 ml of TEN buffer (40 mM Tris-HCl pH 7.5, 10 mM EDTA, 150 mM NaCl) for 15 min at RT to detach the cells from the dish. Once the cells had been collected and pelleted, they were resuspended in 100 µl of lysis-buffer (100 mM Potassium Phosphate buffer ph 7.8, 1 mM DTT, 0.5% Triton) and incubated on ice for 30 min. The lysate was then centrifuged at 4°C, 5 min to eliminate aggregates and the supernatant was transferred to a fresh tube. A fraction of this supernatant was resolved by electrophoresis to check the cellular mass and the amount of protein was quantified. The rest of the cell extract was used to measure the luciferase activity in 200 µl of luciferase buffer (25 mM Glycyl-glycine, 15 mM MgSO~4~, 5 mM ATP, 1 mM DTT, 100 µg/ml BSA) mixed with 20 µl of the cell extract. The luciferine reaction substrate (Promega) was used at a concentration of 1 mM (dissolved in sterile water), and we determined the quantity of luciferase expressed in the cells by measuring the reaction at 560 nm with a luminometer (Monolight® 2010, Analytical Luminescence Laboratory). The values obtained correspond to the mean and standard deviation of three sets of independent experiments. To analyze the induction of β-catenin co-activator function, the values were normalized to controls (corresponding to the ratio transfected/non treated cells).

Immunoprecipitation {#s4g}
-------------------

Inmunoprecipitation assays we carried out on a confluent culture dish of N2a-m cells that were collected in 0.5 ml of immunoprecipitation buffer A (1% Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA pH 8, 1 mM EGTA pH 8, 0.2 mM sodium-*ortho*-vanadate, 0.2 mM PMSF, 0,5% NP-40). After incubation on ice for 30 min, the lysate was centrifuged (16000×g at 4°C, 15 min) to eliminate possible aggregates. The supernatant (100 µl of total native lysate) was incubated in the following buffer: 2% Triton X-100, 20 mM Tris pH 7.4, 2 mM EDTA pH 8, 2 mM EGTA pH 8, 0.4 mM sodium *ortho*-vanadate, 0.4 mM PMSF, 1% NP-40) in the presence of 5 µg of anti-ERα antibody in a total volume of 500 µl. The mixture was incubated for 1 h at 4°C and subsequently, 10 ul of Protein A-Agarose solution (Sigma) was added and incubated at 4°C for 30 min with agitation. The agarose beads were recovered by centrifuging at 16000×g for 4 min at 4°C, and the pellet was washed three times with buffer A and centrifuged (16000×g at 4°C). Finally, the pellet was resuspended in 30 µl of 2× electrophoresis sample buffer (250 mM Tris pH 6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% β-mercaptoethanol), boiled for 10 min and loaded onto an SDS-PAGE gel to be analyzed by western blotting.

Purification of cortical nuclei {#s4h}
-------------------------------

After the dissection of the cortex from 12--16 E18 embryos, the tissue was homogenized in buffer A (0.32 M sucrose, 10 mM Tris pH 7.4, 3 mM MgCl~2~ supplemented with 0.1% Triton-X-100, protease inhibitors, DTT and PMSF). The homogenate was centrifuged at 2500 rpm for 10 min at 4°C, the supernatant was discarded and the pellet was resuspended in buffer A without Triton, and centrifuged in the same conditions. The pellet obtained was resuspended in buffer B (the same as buffer A, but containing 1.9 M sucrose instead of 0.32 M) and homogenized again. The extract was carefully loaded over buffer C (buffer A, but with 2 M sucrose) and spun at 12000 rpm for 60 min at 4°C. The final pellet of the nuclei was resuspended in 50 µl of buffer A, 150 µl of protein extraction buffer (20 mM Tris pH 7.4, 400 mM NaCl, 0.5 mM EDTA pH 8, 0.5 mM EGTA pH 8, 2 mM MgCl~2~) was added and the mix was incubated on ice for 30 min. To finally obtain the soluble fraction of nuclear proteins, the extract was centrifuged at 35000 rpm for 30 min at 4°C and the protein concentration in the extracts was measure using the Lowry reaction.

Electrophoretic Mobility Shift Assays (EMSA) {#s4i}
--------------------------------------------

To obtain nuclear extracts of N2a-m or cortical neurons, cells were grown in serum free-DMEM, without phenol red, to 80% confluence. After washing twice with PBS, 400 µl of EMSA buffer A was added to each P100 dish (10 mM Tris pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,1 mM DTT, PMSF, 1 µM Na~3~VO~4~ and protease inhibitor cocktail). Once two confluent P100 mm dishes were collected in a fresh tube (8 P60 mm in the case of cortical primary neurons), cells were incubated for 15 min on ice and then 40 µl of 10% NP-40 was added and vortexed for 20 sec. The supernatant was centrifuged for 30 sec at 15000 rpm to obtain the cytoplasm fraction. Once dry-resuspended the pellet containing the nuclei, 50 µl of EMSA buffer B (20 mM Tris pH 7.5, 400 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 2 mM MgCl~2~, 1 mM DTT, 0.5 mM PMSF, 1 µM Na~3~VO~4~ and protease inhibitor cocktail) was added at 4°C with vigorous shaking for 15 min. The samples were then centrifuged for 30 sec at 15000 rpm and the supernatant recovered as the nuclear extract. The EMSA assay was performed as described previously [@pone.0005153-Garcia1]. Protein-primer binding was carried out with 20 µg of nuclear proteins during 30 min at RT and a similar amount of each primer (50.000 cpm/µl annealed primer) was added to the reaction at a concentration of 1 mg/ml (sequence forward: 5′-GTCGCCCTTTGATCTTACC-3′, reverse: 5′-GTCGGGTAAGATCAAAGGG-3′, synthetic oligonucleotides from Invitrogen). When antibodies were used in the EMSA assays, 2 µg of antibody against TCF-1-X, TCF-3-X and LEF-1-X (from Santa Cruz) and 1 µg of antibody against β-catenin (Transduction Labs) or 0.8 µg of antibody against ERα (MC-20, Santa Cruz) was added 20 min after the binding reaction had terminated. Competition experiments were performed to recognize the specific bands corresponding to the TCF/LEF-1-DNA complex using TCF/LEF containing the mutated sequence (sequence forward: 5′-GTCGCCCTTTGGCCTTACC-3′, reverse: 5′-GTCGGGTAAGGCCAAAGGG-3′) and unlabelled-wild type TCF/LEF sequence at different final concentrations (20 ng and 100 ng). In all cases, the binding reaction was carried out at a final concentration of 60--65 mM KCl and in the presence of poly dIdC (1 mg/ml) and CHAPS (20%). The results of the binding reaction were analyzed in 4.5% acrylamide/bisacrylamide gels run at constant 130 V and dried (80°C, 1 h).

Total RNA isolation and RT-PCR quantification {#s4j}
---------------------------------------------

Total RNA was isolated from N2a-m cells from a confluent P100 mm dish or from 3 P60 mm dishes in the case of cortical neurons. An additional set of RNA was obtained from N2a-m stable-transfected with pcDNA3-LEF-1 56 or with empty-pcDNA3, either untreated or exposed to estradiol or Wnt3a. RNA was obtained using TRIzol (GIBCO) and it was finally resuspended in sterile-DEPC treated water. The RNA concentration was determined by spectrophotometry at 260 nm, and its integrity was checked using a Bioanalyzer Chip (Agilent). First strand cDNA synthesis was performed on 2 µg of RNA and using the reverse primer as the priming site, hybridized at 37--40°C during 5 min before the remaining reaction components were added: MMLV Reverse-Transcriptase, 2.5 mM DTT, and RT-Buffer (GIBCO) with RNAsin and 10 mM dNTPs. Elongation was performed at 37°C (optimal temperature for the RT enzyme) and the reaction was finally heated to 94°C (5 min) to inactivate the RT enzyme. RT-PCR amplification was performed to analyze cyclin D1, c-myc, actin, β-galactosidase, actin and GADPH expression using the Master SYBR Green I mix (Roche) with 2 mM MgCl~2~ in a lightcycler instrument (Roche Molecular Biochemicals). PCR was performed under optimal conditions for each primer pair. The oligonucleotide sequences and PCR conditions used were as follows: **actin**: 94°C-15 s, 57°C-10 s, 72°C-20 s (forward: 5′-TGTTTGAGACCTTCAACACC-3′; reverse: 5′-TAGGAGCCAGAGCAGTAATC-3′; 600 bp), **cyclin D1:** 94°C-15 s, 55°C-10 s, 72°C-20 s (forward: 5′-CACAACGCACTTTCTTTCCA-3′; reverse: 5′-GACCAGCCTCTTCCTCCAC-3′; 164 bp), **β-galactosidase:** 94°C-15 s, 64°C-5 s, 72°C-15 s (forward: 5′-ATCCTCTGCATGGTCAGGTC-3′, reverse: 5′-CGTGGCCTGATTCATTCC-3′; 315 bp).

Transgenic mice {#s4k}
---------------

The transgenic mice containing the lacZ gene under the control of three consensus TCF/LEF-binding motifs upstream of the c-fos promoter have been described previously [@pone.0005153-DasGupta1] (strain Tg(Fos-LacZ)34Efu/J, JAX®Mice, The Jackson Laboratory) . The genotype of the mice was checked using the following primers and PCR conditions: lacZ rose gene (forward: 5′-ATCCTCTGCATGGTCAGGTC-3′, reverse: 5′-CGTGGCCTGATTCATTCC-3′, 315 bp), endogenous gene (forward: 5′-CAAATGTTGCTTGTCTGGTG-3′; reverse: 5′-GTCAGTCGAGTGCACAGTTT-3′, 210 bp). The mouse colony was maintained in heterozygosis and it was necessary to check each embryo when used for primary neuronal cultures. Accordingly, a portion of the cortex was placed in a mixture containing "Dye Solution" (5 mM K~4~\[Fe(CN)~6~\].3H~2~0, 5 mM K~3~\[Fe(CN)~6~\], 2 mM MgCl~2~) and X-Gal (1 mg/ml).

Microarray analysis {#s4l}
-------------------

Gene expression profiles were generated using Applied Biosystems Mouse Genome Survey Microarray. Total RNA pools were cleaned using the RNeasy kit from Qiagen (Hilden, Germany). Digoxigenin-UTP labeled cDNA probes were generated and linearly amplified from 1 µg of each RNA pool using Applied Biosystems Chemiluminescent RT-IVT labeling Kit. Microarray hybridization, chemiluminescence detection, image acquisition and analysis were done according to Applied Biosystems protocols and the 1700 Chemiluminescent Microarray Analyzer.

Applied Biosystems Expression System software was used to extract Assay Signal, and Assay Signal to Noise ratio values from the microarray images. Bad spots flagged by the software were removed from the analysis. The Assay Signal of the represented genes was ***log*** transformed, loess-normalized (<http://www.bioconductor.org>) and further filtered by standard Expression Array System Signal to Noise threshold (S/N greater than 3 in at least one sample). The expression profiles of the two control populations (N2a-m stable-cell lines with or without ΔLEF-1) were compared with the corresponding population, treated with either estradiol or Wnt3a.

Supporting Information {#s5}
======================

###### 

N2a-m cells express both the ERα and ER{lower caes beta} isoforms of the estrogen receptor and they respond to estradiol. Immunocytochemistry with anti-ERα and ERβ identified a different cytoplasmic location for the two isoforms in both cell lines. While ERα presented was diffusely distributed throughout the cytosol and nucleus, and it accumulated in the nucleus after the addition of estradiol (A--B). ERβ distribution was more heterogeneous and it could be found in aggregates, diffusely distributed in the cytosol or in the nucleus(C--D). The addition of estradiol (B and D) increases the immunoreactivity against two receptors in the nucleus. Images were analyzed by confocal microscopy and western blotting confirmed the expression of both isoforms in total cell extracts from control cells.

(9.68 MB EPS)

###### 

Click here for additional data file.

###### 

Distribution of β-catenin after exposure of N2a-m cells to estradiol does not reveal the translocation of β-catenin to the nucleus. Cell fractions corresponding to the soluble, membrane and nuclear fractions were analyzed in control and estradiol treated cells. Neither 30 nor 60 min exposure to estradiol provoked the nuclear accumulation of β-catenin, statistically significant. In contrast, recruitment of β-catenin to the membrane fraction was more evident. We also checked the movement of ERα as a control of the assay, which clearly accumulated in the nuclear fraction (see [Figure 8](#pone-0005153-g008){ref-type="fig"}).

(2.36 MB EPS)

###### 

Click here for additional data file.

###### 

N2a-m cells are responsive to Wnt3a protein. (A)- N2a-m cells respond to Wnt3a (20 ng/ml) with the accumulation of β-catenin and with a maximal effect observed after 90--120 minutes. (B)- The transcriptional activity of β-catenin was analyzed with the TCF-luc reporter. Luciferase activity was calculated at different concentrations of Wnt3a protein, as indicated above, and Wnt3a produced a significant increase in β-catenin/TCF dependent transcription. Asterisk represents P value from Student\'s t-test: \* (P≤0.05), when compared the two Wnt concentrations; and \*\* (P≤0.01) when compared with control.

(1.61 MB EPS)

###### 

Click here for additional data file.

###### 

Neither ERα nor TCF-3 antibodies modify the migration of nuclear protein extracts from N2a-m cells exposed to estradiol or Wnt3a. Nuclear protein extracts were obtained from control or estradiol/Wnt3a treated cells as indicated in each lane. The incubation with specific antibodies against ERα or TCF3 did not produce a higher molecular weight band that migrated more slowly than that previously identified as a TCF-DNA complex, nor did they prevent the formation of the complex.

(2.50 MB EPS)

###### 

Click here for additional data file.
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